First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

For the past two decades, platinum-based combination chemotherapy has been the standard-of-care, first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) without mutations that were sensitive to targeted therapy. However, chemotherapy has provided only a moderate benefit,…

http://ift.tt/2rFhC6Z